INTRODUCTION
reported. 8, 9 A new triterpenoid trisaccharide and three new triterpenoids have been isolated from this plant. 10, 11 The antimicrobial activity of saponins and a new flavan glycoside have been reported from this plant. 12, 13 Previously, we have reported the protein kinase inhibitory activity of Acanilol 2, a new Peltogynoid isolated from the bark of Acacia nilotica 14 and recently, we also reported that the ethylacetate soluble fraction and two compounds isolated from the fraction inhibited a panel of protein kinases and (+)-catechin showed tissue necrosis of some tumoral cell. 15 In our continuing investigation of the genus acacia for protein kinase inhibitory constituents, we report herein the activity of the extract, fractions and the isolated flavonoid from the active ethylacetate soluble fraction of the stem bark of Acacia auriculiformis against a panel of some disease related protein kinases.
MATERIALS AND METHODS

General experimental procedures
Column chromatography was performed on silica gel G (200-400 mesh, Silicycle), Thin layer chromatography was performed on pre-coated TLC plate silica gel 0.2mm aluminium backed (Silicycle), NMR spectra was performed on a Bruker DRX 400 MHz spectrophotometer in CD 3 OD using TMS as internal standard, while LC-MS was carried out using an ESI-LTQ-orbitrap discovery XL mass spectrometry.
Plant material
The plant consisting of the leaves and stem bark were collected in Zaria in the month of July and were authenticated at the herbarium section of the Biological Science Department, Ahmadu Bello University, Zaria, where a voucher specimen was deposited. Extraction and isolation The dried pulverised stem bark (400 g) was extracted with chloroform (2X2L) at room temperature and the solvent removed at reduced pressure to give a 0.6 g (2.4%) of chloroform extract. The marc was then extracted to exhaustion with 70% ethanol to give a brown solid mass of ethanol extract 47 g (11.8%). A portion of the ethanol extract 27g was suspended in 300 ml of distilled water and successfully extracted with 50 mlx8 of ethylacetate and 50mlx8 of n-butanol and removal of the solvents at reduced pressure afforded a dark brown solid mass (3.5 g) of ethylacetate fraction and a brown sold mass of n-butanol fraction which weighed 5.4 g. A portion of the chloroform, ethylacetate and n-butanol fractions were investigated for protein kinase activity against a panel of diseased related protein kinases. The active ethylacetate fraction (2 g) was packed in a column of (3cmx50cm) and elution commenced gradiently with n-hexane and n-hexane dichloromethane mixtures followed with dichloromethane and dichloromethane: methanol mixtures. The progress of elution was monitored on thin layer chromatography using the solvent systems I and II which consists of ethyl acetate: dichloromethane: methanol: water (15:8:4:1) and ethyl acetate: dichloromethane (1:1) respectively. Fractions eluted with 5% methanol in dichloromethane which were homogenous on TLC plates were pooled together and purified over sephadex LH-20 eluting with methanol to afford compound I, a yellow solid (3mg). The compound was identified by spectroscopic data ( 
Protein kinase inhibitory studies
A portion of the chloroform, ethylacetate and n-butanol fractions and compound I were screened against a panel of diseased related protein kinases. Kinase activity were assayed in appropriate buffer, with either protein or peptide as substrate in the presence of 15µM ( 33 -P) ATP (3,000Ci/mmol; 10mCi/ml) in a final volume of 30µL following the assay as described. 16 Controls were performed with appropriate dilutions of dimethyl suphoxide. Full length Kinases were used unless specified. Peptide substrates were obtained from Proteogenix (Oberhausbergen, France). Hs CDK2/Cyclin A (cyclin-dependent kinase-2, human, kindly provided by Dr. A. Echalier-Glazer, Leicester, UK) was assayed in buffer A (+0.15 mg/mL of BSA +0.23 mg/mL of DTT) with 0.8 µg/mL of histone H1 as substrate. HsCDK9/Cyclin T (human, recombinant, expressed by baculo virus in S19 insect cells was assayed in buffer A (+0.15 mg/ml of BSA +0.23 mg/ ml of DDT) with 0.27 µg/mL of the following peptide: YSPTSPSYSPTSP-SYSPTSPSKKKK, as substrate. HsCDK5/p25 (human, recombinant, expressed in bacteria) was assayed in buffer B, with 0.8 µg/µL of histone H1 as substrate. HsPIM1 (human proto-oncogene, recombinant, expressed in bacteria) was assayed in buffer B, 0.8 µg/µL of histone H1 (Sigma #H5505) as substrate. HsHaspin-kd (human, kinase domain, amino acids 470 to 798, recombinant, expressed in bacteria) was assayed in buffer H with 0.007 µg/ µL of Histone H3 (1-21) peptide (ARTKQTARKSTGGKAPRKQLA) as substrate. HsRIPK3 (human, recombinant, expressed in Sf9 insect cells) was assayed in buffer R with 0.1 µg/µL of MBP as substrate. HsAuroraB (human, recombinant, expressed by baculovirus in S19 insects' cells, Signal Chem, product #A31-10G) was assayed in buffer D with 0.2 µg/µL of MBP as substrate. SscGSK-3α,β (glycogen synthase kinase-3, porcine brain, native, affinity purified) was assayed in buffer A (+0.15 mg/mL of BSA +0.23 mg/mL of DTT ), with 0.010 µg/µL of GS-1 peptide, a GSK-3 selective substrate (YRRAAVPPSPSLSRHSSPHQSpEDEEE, sp satands for phosphorylated serine). SscCK1δ/€ (casein kinase 1δ/€, porcine brain, native, affinity purified) was assayed in buffer B, with 0.022 µg/µL of the following peptide: RRKHAAIGSpAYSITA as CK1 -specific substrate). RnDYRK1A-kd (Rattus norvegicus, amino acids 1 to 499 including the kinase domain, recombinant, expressed in bacteria, DNA vector provided by Dr W. Becker, Aachen, Germany) was assayed in buffer A (+0.5 mg/mL of BSA +0.23 mg/mL of DTT) with 0.033 µg/µL of the following peptide :KKISGRLSPIMTEQ as substrate. MmCLK1 (from Mus musculus, recombinant, expressed in bacteria) was assayed in buffer A (+0.15 mg/ml of BSA + 0.23 mg/ml of DTT) with 0.027 µg/µL of the following peptide: GRSRSRSRSRSR as substrate. PfGSK-3 (from Plasmodium falciparum, recombinant, expressed in bacteria) was assayed in Buffer A (+0.15 mg/mL of BSA +0.23 mg/mL of DTT) with 0.010 µg/µL of GS-1 peptide, a GSK-3-selective substrate (YRRAVPPSPSLSRHSSPHQSpEDEEE, sp stands for phosphorylated serine). LdTLK (tousled -like kinase, from Leishmania donovani, recombinant, expressed in bacteria), was assayed in buffer K with 0.6 µg/µL of casein dephosphorylated from bovine milk (Sigma #C4032) as substrate. LmCK1 (from Leishmania major, recombinant, expressed in bacteria was assayed in buffer B (adjusted at pH 8) with 0.028 µg/µL of the following peptide: RRKHAAIGSpAYSITA as CK1-specific substrate.
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RESULTS
Compound 1 was isolated as a yellow solid (3 mg). Its spectral data (
1 H,-NMR and LC-MS) are consistent with literature data for 3, 4' , 7 ,8-tetrahydroxyflavone.
Effects of the extract/fractions on the activity of diseaserelated protein kinases Table 1 show the results of the primary screening of the chloroform extract, ethyl acetate-n-butanol soluble fractions and compound I against a panel of protein kinases. The result indicates the activity that remains in the tube after treating the mentioned kinase with 50µg/mL of the extract/fraction compared to control assay treated with DMSO. The result revealed that the chloroform extract showed the least activity against the kinases as the extract did not inhibit the activity of the kinases and hence the high % activity of each kinase remaining in the tube this can be observed on the activity of the extract against Pim1 which showed 91% of the activity of the kinase still remaining in the tube after treatment with 50µg/mL of the extract in comparison with the control. The ethyl acetate and n-butanol fractions in contrast, however showed a reduction in kinase activity in the tube after treating the mentioned extract with 50µg/mL of the fraction. In Table 1 , the ethyl acetate fraction on Pim1 showed only 2% of remaining activity of the kinase in the tube compared to DMSO. A similar trend was observed in n-butanol fraction. The isolated flavonoid also shows some inhibitory activity against all the kinases tested. The ethyl acetate, n-butanol fractions and compound I were next evaluated over a wide range of concentrations from 0.016µg/mL to 50µg/mL and IC 50 values were determined from the dose response curves (Sigma-plot). The results of the in vitro enzymatic activity assay were summarised in Table 2.  Table 2 shows the inhibitory activity of the ethylacatetate, n-butanol fractions and isolated flavonoid against the mentioned kinases with their IC 50 . The result revealed that the ethylacetate fraction is the most active with IC 50 of 1.0µ/mL against Haspine kinase followed with Hs CDK9 with an IC 50 of 4.5µg/mL. The activity of the ethylacetate fraction is more than n-butanol fraction.
DISCUSSION
Compound 1 was isolated as a yellow solid, its mass spectral data gave a molecular ion peak at m/z 286 that depict a molecular formula Table 1 (Figure 1 ),the spectra compares well with literature. 17 This is the first report of this flavonoid from Acacia auriculiformis. This compound has been isolated previously from Acacia rhodoxylon. 18 Primary screening of the isolated compound against eight disease related protein kinases (Table 1) indicates that the compound inhibited more than 50% activity of all the kinases, for example against DYRK1A and PIM 1 kinases, the compound inhibits 89% and 90% total kinase activity respectively. Table  2 shows the IC 50 values for compound 1 when tested over a wide range concentration from 0.016 to 50 µg/ml. The table reports the inhibitory activity of the compound against the mentioned kinases. The compound was active against six out of 8 kinases tested; however, the compound was found to be inactive against Haspine and CDK5 kinases, the IC 50 values of the compound against DYRKIA and CDK9 was estimated at 2.05 and 2.28 µg/ml respectively indicating that the isolated flavonoid is a DYRK1A and CDK9 inhibitor. Flavonoids have been shown to have the ability to modify or modulate the activities of some enzymes involved in cell surface signal transduction, immune function and transformation, tumor growth and metastasis. 19, 20 The inhibitory effect of flavonoids in growth of malignant cells could be a consequence of their interference with protein kinase activities involved in the regulation of cellular proliferation and apoptosis.
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CONCLUSION
The ethylacetate of fraction of Acacia auriculiformis was shown to be the most active among the three extract/fractions investigated for protein kinase inhibitory activity and from the ethylacetate fraction, 3, 4' , 7, 8-tetrahydroxyflavone was isolated and was found to be a DYRK1A and CDK9 inhibitor. This result might justify the cancer and inflammation potentials of this plant.
